The Ordinary has launched its first-ever eye cream, formulated around PDRN — the polynucleotide ingredient that has gone viral across skin-care social channels — and backed the launch with a "playful" pop-up in its home market, Cosmetics Business reports.

For formulators and buyers, the significance is straightforward: PDRN (polydeoxyribonucleotide, typically derived from salmon sperm DNA) has so far lived mostly in clinic-only injectables and premium K-beauty and aesthetic-medicine channels. The Ordinary, Deciem's low-price, high-transparency brand, moving it into a mass-accessible eye cream marks a further step in the ingredient's migration from professional treatment rooms to retail shelves.

What does the launch change?

The Ordinary built its reputation on single-ingredient transparency — niacinamide, hyaluronic acid, retinal — at single-digit price points, with full INCI disclosure on every label. Adding PDRN to that model exposes the ingredient to the brand's notoriously ingredient-literate consumer base, who will scrutinise:

• the concentration declared or implied on-pack;
• the INCI naming of the polynucleotide used;
• whether the claim set stays cosmetic (moisturisation, barrier, appearance of fine lines) or drifts toward the regenerative language used in aesthetic clinics.

That scrutiny matters for the wider market. When The Ordinary adopts an ingredient, it typically normalises it: niacinamide and azelaic acid both saw search and formulation upticks after the brand's entries. PDRN suppliers should expect inbound interest from mass and masstige brands looking to match the launch.

Why the pop-up matters

The brand framed the activation as "playful", tying the retail experience directly to the virality that made PDRN famous on TikTok and Instagram, where salmon-DNA skincare and "skin boosters" have racked up large audiences over the past two years.

For procurement and marketing teams, the signal is that viral ingredient demand now converts fastest through experiential retail rather than digital-only campaigns. An eye cream — a low-risk, high-frequency entry point — is the logical first vehicle for a first-time active in a brand's line-up.

What to watch next

The data points to monitor: whether The Ordinary discloses the PDRN percentage in its usual direct-label style; whether competing masstige players file their own polynucleotide launches within the next two launch cycles; and whether regulators or claim-review bodies push back on regenerative framing borrowed from the injectables space.